SYGNIS licenses amplification buffer to QIAGEN
(Thomson Reuters ONE) -
SYGNIS Pharma /
SYGNIS licenses amplification buffer to QIAGEN
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Agreement follows a global licence agreement signed with QIAGEN in 2012.
* First non-exclusive licence agreement for a new amplification buffer
developed by Professor Salas at the CSIC laboratory.
Madrid/Heidelberg, 16 May 2013 - Spanish-German biotech company SYGNIS Pharma AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard segment of the German Stock
Exchange) has signed a licence agreement for the distribution of a new
amplification buffer with QIAGEN, the global leader in sample and assays
technologies. This is the second agreement with QIAGEN within 9 months and the
first licence agreement for the amplification buffer technology developed by the
team led by renowned Professor Margarita Salas at the CSIC laboratory.
The recently granted licence covers a new amplification buffer, a tool used in
isothermal amplification, providing superior reaction performance.
"With the new agreement, SYGNIS adds a global reference in the sector in the
fields of DNA amplification research and commercial markets. This newly signed
agreement shows that SYGNIS is making progress in the commercialization of core
technologies and products designed for the DNA sequencing and amplification
market. It strengthens the network of relationships we maintain with life
science and diagnostics companies in the DNA amplification industry," SYGNIS'
CEO Pilar de la Huerta commented.
Background
In July 2012, through X-POL, SYGNIS reached an exclusive global licence
agreement with QIAGEN for the distribution of the polymerase QualiPhi(®).
QualiIPhi(®) is an upgraded version of phi 29 DNA polymerase. Compared to
similar polymerase proteins on the market, the new one exhibits enhanced
properties. Being less time-consuming and having highly superior performance
characteristics, the method developed by SYGNIS enables DNA amplification from
concentrations as low as those found in a single cell. This is extremely useful
in cancer research, among other applications.
Polymerase proteins are the main tool for amplifying long DNA fragments and
whole genomes, and are basic in research involving analysis and modification of
DNA from any species.
About SYGNIS Pharma AG: www.sygnis.de
After the merger in 2012 between X-Pol Biotech, specialising in DNA
amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock
Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new
mission is to develop and distribute technologies and products from X-Pol, which
has a commercial product in the DNA amplification segment, QualiPhi(®) and is
currently developing other products in the field of Next Generation
Sequencing.//
For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta(at)sygnis.es
# # # Disclaimer:
Some statements included in this press release, relating neither to proven
financial results nor to other historical data, should be viewed as forward-
looking, i.e. not definitive. Such statements are mainly predictions of future
results, trends, plans or goals. They should not be considered to be total
guarantees since given their very nature, they are subject to known and unknown
risks, as well as to aspects beyond human control, and can be affected by other
factors as a consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or implied
predictions contained in such statements. SYGNIS does not undertake to publicly
update or revise said statements in light of new information or future results
or for any other reason. # # #
Press release (PDF):
http://hugin.info/150277/R/1702512/562593.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SYGNIS Pharma via Thomson Reuters ONE
[HUG#1702512]
Unternehmensinformation / Kurzprofil:
Datum: 16.05.2013 - 10:29 Uhr
Sprache: Deutsch
News-ID 260740
Anzahl Zeichen: 5110
contact information:
Town:
Heidelberg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SYGNIS licenses amplification buffer to QIAGEN"
steht unter der journalistisch-redaktionellen Verantwortung von
SYGNIS Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
